Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vijaya Diagnostic reported strong Q4 FY'26 results with revenue of INR 219 crores (26.6% Y-o-Y growth) and EBITDA of INR 95.5 crores with 43.5% margin (up 379 bps Y-o-Y). For FY'26 full year, revenue crossed INR 800 crores at INR 814 crores (19.5% growth) with EBITDA margin of 41.4%. The company doubled its center count from 81 to 162 over 5 years and expanded from 2 to 6 states. Management guided FY'27 capex of INR 140-150 crores for 4-5 new hubs and 10-12 spokes plus an automated lab in Hyderabad. They maintained EBITDA margin guidance above 40%, with Hyderabad growing 20% in Q4 due to operating leverage. Pune cluster showed recovery with 16% Y-o-Y growth. The company plans to add genomic testing capabilities and a flagship center in Bangalore with high-end equipment.
Strong operational execution with margin expansion demonstrates effective cost management and operating leverage. The conservative 40% EBITDA margin guidance suggests management remains focused on sustainable growth while continuing network expansion. The robust cash position of INR 280-300 crores provides flexibility for future M&A opportunities.